Medication-assisted treatment for opioid use disorder is the most evidence-backed approach available for ending dependence on heroin, fentanyl, or prescription painkillers, and understanding how a MAT program for opioid use disorder actually works makes the difference between knowing you have options and knowing how to use them.
What Is a MAT Program for Opioid Use Disorder
A MAT program combines FDA-approved medications with counseling and behavioral therapies to treat opioid use disorder as the medical condition it is. The medications reduce cravings, prevent withdrawal, and stabilize brain chemistry. The behavioral support addresses the psychological patterns, trauma, and social circumstances that surround addiction. Together, these two components form a treatment approach that outperforms every alternative by a significant margin.
The stakes are not abstract. According to the CDC, drug overdose deaths in the United States exceeded 107,000 in 2023, with synthetic opioids, primarily fentanyl, driving the vast majority of those fatalities. In Maryland specifically, opioid-related overdose deaths have remained persistently high, making access to effective treatment not just a personal priority but a public health urgency. MAT exists precisely because less intensive approaches have not been enough.
How MAT Differs from Detox Alone
Detox is the process of clearing opioids from the body. What it does not do is treat the underlying disorder. A 2020 analysis published in JAMA Psychiatry found that patients who completed detox without follow-on medication had relapse rates exceeding 90% within the first year. The problem is not willpower. Opioids physically alter the brain’s reward and stress systems, and those changes do not reverse because the drugs are no longer present. Without medication to stabilize those systems, the brain remains in a state of dysregulation that makes sustained recovery extraordinarily difficult.
What this means in practice: if someone you care about is considering detox as their entire treatment plan, that plan carries serious risk. MAT does not make recovery easier by removing the hard work. It makes recovery possible by treating the actual disease rather than just its most visible symptom.
Why the Term MOUD Is Gaining Ground
You may encounter two terms used to describe the same treatment approach: MAT (medication-assisted treatment) and MOUD (medications for opioid use disorder). The shift toward MOUD reflects a clinical and philosophical point. The word “assisted” implies that medication is a support tool for some other primary treatment, whereas the evidence actually positions medication as the primary treatment itself. SAMHSA and many clinical bodies now prefer MOUD for this reason. Both terms refer to the same medications, the same counseling integration, and the same overall approach. You will see both used throughout Maryland’s treatment system.
The Three FDA-Approved Medications Used in MAT
Three medications have FDA approval for treating opioid use disorder: methadone, buprenorphine, and naltrexone. Each works through a different mechanism, and each suits a different patient profile. Matching the right medication to the right person requires a clinical evaluation, not a default choice. Here is how each one works.
Methadone
Methadone is a full opioid agonist, meaning it activates the same brain receptors that other opioids do, but at therapeutic doses it does so without producing euphoria. The result is that cravings and withdrawal symptoms are suppressed while the patient remains clear-headed and functional. A landmark study by Dole and Nyswander, replicated extensively since, established methadone maintenance as one of the most effective long-term treatments for opioid dependence, with patients showing dramatic reductions in illicit drug use and criminal activity.
The significant logistical consideration with methadone is how it is dispensed. Federal law requires that methadone for opioid use disorder be distributed through licensed opioid treatment programs (OTPs), also called methadone clinics. This means daily in-person dosing at an approved clinic, at least initially. Patients who demonstrate stability over time become eligible for take-home doses. In Maryland, OTP clinics operate in most major metro areas, though rural access remains limited. For patients with significant opioid histories, severe withdrawal symptoms, or prior treatment failures, methadone is often the most appropriate starting point.
Buprenorphine
Buprenorphine is a partial opioid agonist. It activates opioid receptors but only partially, which creates a ceiling effect: above a certain dose, the drug stops producing additional effects. That ceiling dramatically reduces the risk of respiratory depression and overdose compared to full agonists. Most buprenorphine formulations also include naloxone, an opioid antagonist added specifically to deter injection misuse. Suboxone, the most widely prescribed combination product, is taken as a sublingual film that dissolves under the tongue.
The most important practical distinction between buprenorphine and methadone is where you can get it. A 2022 study in Health Affairs found that office-based buprenorphine prescribing dramatically improved treatment access for patients in communities with limited clinic infrastructure, particularly in suburban and rural areas. Because buprenorphine can be prescribed by any licensed provider who has completed the required training, treatment can happen in a primary care office, a telehealth appointment, or a dedicated outpatient clinic. For someone juggling a job, childcare, or transportation barriers, that flexibility is not a minor convenience. It is what makes treatment viable.
For a closer look at how buprenorphine works in a Maryland treatment context, this overview of office-based opioid care covers the specifics of what to expect from a prescriber-led program.
Naltrexone
Naltrexone is an opioid antagonist. It does not activate opioid receptors at all. Instead, it blocks them completely, so that if opioids are used while naltrexone is active, they produce no effect. There is no abuse potential and no physical dependence associated with naltrexone itself. It comes in an oral daily form and as Vivitrol, a monthly injectable that removes the daily adherence burden.
The non-negotiable condition for starting naltrexone is a complete detox from opioids beforehand, typically a minimum of seven to ten days clear of short-acting opioids and longer for methadone. Attempting to start naltrexone without completing detox causes precipitated withdrawal, which is severe and immediate. A 2018 study published in the New England Journal of Medicine comparing extended-release naltrexone to buprenorphine-naloxone found comparable outcomes in patients who successfully completed induction on both medications, though dropout during the naltrexone induction phase was notably higher. Naltrexone tends to be well-suited for patients who have already completed a medically supervised detox, who have strong motivation and support systems, and who prioritize a non-opioid treatment approach.
How the MAT Program Actually Works, Step by Step
No two patients enter treatment with identical histories, and no two leave it on the same timeline. What MAT programs share is a structured progression: evaluation, induction, stabilization, and ongoing maintenance. Understanding each phase helps set realistic expectations before the first appointment.
Initial Evaluation and Diagnosis
The first appointment is a clinical assessment, not a formality. A provider will take a full substance use history, including what opioids have been used, how frequently, by what method, and for how long. A mental health screening reviews for depression, anxiety, PTSD, and other co-occurring conditions. A physical health review covers any medical conditions, current medications, and relevant history. Social factors, housing, employment, family support, and legal involvement, are part of the picture too.
According to SAMHSA’s Treatment Improvement Protocol 63, the comprehensiveness of this initial assessment directly predicts treatment retention and outcomes. The reason is straightforward: a provider who only knows your opioid use history cannot prescribe with the same precision as one who understands the full clinical picture. Bring as much information as you can to this appointment. Honesty about everything, including polysubstance use, mental health history, and past treatment attempts, gives the care team what they need to build the right plan.
Starting Medication: Induction
Induction is the process of introducing the medication for the first time. For buprenorphine, timing is everything. Buprenorphine is a partial agonist with high receptor affinity, meaning it displaces other opioids from receptors. If taken while full opioids are still active in the system, it triggers precipitated withdrawal: sudden, severe, and deeply uncomfortable. To avoid this, providers use a clinical tool called the COWS scale (Clinical Opiate Withdrawal Scale) to measure withdrawal severity before the first dose. The patient needs to be in mild-to-moderate withdrawal before buprenorphine is introduced.
Methadone induction works differently. Because methadone is a full agonist, it does not risk precipitated withdrawal in the same way, but dosing must be conservative at the start to avoid accumulation and toxicity. Starting doses are carefully calibrated and increased gradually over days. Tell your care team exactly what opioids you have been using, including any fentanyl exposure, as fentanyl’s longer tissue retention affects induction timing for both medications.
Stabilization and Dose Adjustment
Stabilization is the phase where the goal shifts from preventing withdrawal to finding the dose that keeps you comfortable, functional, and free from cravings. This takes time, and it is not linear. Some patients find their stable dose quickly. Others need several weeks of adjustments. A 2014 study in Drug and Alcohol Dependence found that adequate buprenorphine dosing, meaning doses high enough to genuinely suppress cravings rather than just prevent withdrawal, was strongly associated with treatment retention and reductions in illicit use.
What stable feels like is not what the first week feels like. The first days on medication often bring physical adjustment: mild sedation, disrupted sleep, digestive changes. Those side effects typically resolve. What you are working toward is waking up without the preoccupation with using, being able to hold a conversation without craving dominating your attention, and functioning in daily life. The practical step during this phase is honest communication with your provider about what you are still feeling, not just about side effects but about cravings. Undertreated cravings are the main reason people leave treatment early.
Counseling and Behavioral Health Support
Medication stabilizes the brain. Counseling addresses everything else. A MAT program integrates behavioral support in several forms: individual therapy to work through triggers, trauma, and thinking patterns; group counseling that builds accountability and community; peer support from people who have navigated recovery themselves; and case management to address the social determinants, housing, employment, and legal issues, that affect treatment outcomes.
A 2018 Cochrane review of MAT outcomes found that adding psychosocial treatments to medication produced measurable improvements in treatment retention and reduction in illicit drug use compared to medication management alone. Among the behavioral components studied, contingency management, which reinforces clean toxicology screens with concrete rewards, had the strongest retention data in that review. The practical takeaway: if your MAT program offers contingency management or structured peer support, those are not optional add-ons. They are part of what makes the difference.
Ongoing Maintenance and Long-Term Treatment
One of the most common misunderstandings about MAT is that the goal is to taper off medication as quickly as possible. For many people with opioid use disorder, long-term or indefinite maintenance is not a failure. It is appropriate medical treatment, identical in principle to a diabetic patient staying on insulin.
A 2021 study in Addiction found that patients who discontinued buprenorphine in the first two years of treatment had relapse rates more than four times higher than those who remained on medication. The evidence does not support early discontinuation as a goal in itself. The question of how long to stay on medication is a clinical one to work through with your provider based on your individual stability, life circumstances, and goals. Reframing the question from “when do I get off this medication” to “what does my provider say my risk looks like right now” is a more useful starting point.
What MAT Does to the Brain and Body
Opioid use disorder is a brain disease in the clearest sense of the term. Opioids hijack the brain’s reward system by flooding dopamine circuits, and over time the brain adapts by reducing its own natural dopamine production and down-regulating opioid receptors. When opioids are removed, the brain is left depleted: flat, anxious, physically painful, and driven by powerful compulsion to restore the chemistry it has come to depend on.
According to the National Institute on Drug Abuse (NIDA), MAT medications work by occupying opioid receptors in a way that prevents the highs and lows of active use while allowing the brain’s homeostatic systems to gradually stabilize. Physical stabilization is not the end of treatment. But it is the precondition for everything else. You cannot engage meaningfully in therapy when you are in withdrawal. You cannot rebuild relationships, pursue employment, or address trauma when your brain is screaming for relief. MAT creates the neurological ground floor on which everything else in recovery is built.
The Role of Co-Occurring Mental Health Conditions in MAT
A substantial share of people with opioid use disorder also live with depression, anxiety, PTSD, or other mental health conditions. This is not coincidental. Many people begin using opioids partly as self-medication for psychological pain, and the neurological damage of prolonged opioid use compounds those underlying conditions.
A 2019 study in the Journal of Substance Abuse Treatment found that patients with untreated co-occurring mental health conditions had significantly lower MAT retention rates and higher rates of relapse compared to those who received integrated care. Treating addiction and mental health separately, referred to as sequential treatment, consistently underperforms integrated models where both are addressed simultaneously. What this means at your first appointment: do not minimize or omit mental health history. Anxiety, depression, trauma, sleep disorders, and past psychiatric treatment all belong in that conversation. A provider who knows the full picture can build a treatment plan that addresses both conditions, and finding a program built around that kind of coordinated care is worth the effort.
Common Misconceptions About MAT
The biggest barriers to MAT are not logistical. They are the persistent myths that discourage people from starting or staying in treatment.
“Isn’t This Just Substituting One Drug for Another?”
This is the most common objection, and it rests on a misunderstanding of what addiction is. According to SAMHSA’s definition, addiction is characterized by compulsive use despite harmful consequences, loss of control, and continued craving. MAT medications, taken as prescribed, eliminate all three of those features. There is no intoxication, no compulsive behavior, no escalation to obtain the drug. What remains is physical dependence, which is a normal bodily response to certain medications and is clinically distinct from addiction.
A useful analogy: no one argues that a person with hypertension is “substituting one drug for another” when they take a daily blood pressure medication. The medication manages a chronic condition. MAT does the same. If a family member raises this concern, the clearest answer is that the medications used in MAT treat a chronic brain disease the same way other medications treat other chronic diseases.
“Does MAT Mean I’m Not Really in Recovery?”
SAMHSA defines recovery as “a process of change through which individuals improve their health and wellness, live self-directed lives, and strive to reach their full potential.” That definition does not require abstinence from all medications. It centers health, function, and quality of life.
The abstinence-only model of recovery has strong cultural roots but weak evidence. Requiring abstinence from MAT medications as a condition of being considered “in recovery” has driven people out of treatment programs and into relapse. If you or someone you love carries this belief, the reframe worth offering is this: if the medication allows you to be present for your family, hold a job, sleep, and engage in therapy, that is recovery.
“Can’t I Just Detox and Skip the Medication?”
You can, but the data is unambiguous about what follows. The CDC and SAMHSA both report that the period immediately following detox carries the highest overdose mortality risk of the entire treatment continuum. Tolerance drops rapidly during detox, and if relapse occurs at pre-detox use levels, the risk of fatal overdose is acute. In the fentanyl era, that risk is compounded because fentanyl’s potency means that a relapse dose that would previously have been survivable is now frequently fatal. Choosing not to use medication is a clinical decision that belongs in a conversation with a provider, not a willpower demonstration.
Who Qualifies for a MAT Program
The general eligibility criteria for a MAT program are: a diagnosis of opioid use disorder using DSM-5 criteria, a willingness to engage in treatment, and a medical evaluation to identify the appropriate medication. There is no minimum severity threshold. You do not need to have hit a specific low point or used for a certain number of years.
In Maryland, Medicaid covers MAT, including both medications and the associated counseling and case management services. Commercial insurance plans cover MAT under federal mental health parity laws. For patients without insurance, options exist through sliding-scale programs and state-funded treatment. To prepare for a first appointment, bring any insurance information you have, a list of current medications, and as clear a picture as you can give of your substance use history. You do not need a referral to access most outpatient MAT programs. Understanding what the first steps look like before you call can make that call feel less daunting.
MAT for Specific Opioids: Heroin, Fentanyl, and Prescription Painkillers
MAT applies to all forms of opioid dependence. The underlying neurological process is the same whether the opioid is heroin, oxycodone, hydrocodone, or fentanyl. The clinical picture, however, differs meaningfully based on the specific substance.
Fentanyl has changed MAT practice in ways that are still being studied and codified. Because fentanyl is 50 to 100 times more potent than morphine and accumulates in fatty tissue, it remains detectable and pharmacologically active longer than shorter-acting opioids. This has two practical consequences. First, standard buprenorphine induction timelines, designed around heroin and prescription opioid users, may not allow enough withdrawal time before induction, increasing precipitated withdrawal risk. Second, higher buprenorphine doses are often needed to achieve adequate receptor occupancy in patients with significant fentanyl exposure.
A 2022 clinical guidance document from the American Society of Addiction Medicine addressed these challenges directly, recommending low-dose buprenorphine induction protocols (sometimes called Bernese method induction) for patients with known or suspected fentanyl use. The practical step: tell your provider explicitly if fentanyl is or may be involved in your opioid use, including if you have been using street drugs that may contain it unintentionally. That information shapes induction timing and initial dosing in ways that matter for your safety and comfort.
What the Evidence Says About MAT Outcomes
The evidence base for MAT is, at this point, extensive and consistent. A 2019 meta-analysis published in The Lancet found that both methadone and buprenorphine reduced illicit opioid use by approximately 50% compared to no medication treatment, and reduced overdose mortality by roughly 50% as well. A separate 2020 study in JAMA Network Open found that patients engaged in buprenorphine treatment had a 38% lower risk of opioid overdose compared to patients who received no medication.
What success in MAT looks like month by month is not dramatic. In the first weeks, it looks like sleeping through the night without withdrawal symptoms. In the first month, it looks like being able to hold a conversation without cravings running in the background. In the first three months, it looks like rebuilding routines, reengaging with family, and beginning to address the things that were put on hold. The big outcome metrics, sustained reduction in illicit use, lower overdose risk, improved employment and housing stability, emerge over a year or more of consistent treatment. That timeline is not a sign of slow progress. It is the normal clinical arc of treating a chronic condition.
Connecting with a prescriber who specializes in this kind of ongoing care from the start positions you for that longer arc, rather than treating each appointment as a standalone event.
The Move That Matters Most Right Now
The single most evidence-supported action you can take today is making the first call to a MAT provider. Not researching every option, not waiting for the right moment, and not completing a detox first. Research consistently shows that treatment entry during a window of motivation, before that motivation is tested by withdrawal or circumstance, produces better retention outcomes than delayed entry.
MD M.A.T.T. offers same-day and next-day intake across multiple Maryland locations, accepts Medicaid and all insurance, and handles the logistics that usually slow people down: confirmed pharmacy pickup for your medication and transportation arranged through your insurance. More than 92% of new patients remain in treatment, a number that reflects what happens when the structural barriers to staying in care are removed.
If you have questions about what the intake process looks like or want to understand your insurance coverage before calling, that information is available. But the most important move is the call itself.